Bain Capital Specialty Finance, Inc. PLEASE CONSIDER THE FOLLOWING In this material Bain Capital Credit, LP, Bain Capital Credit (Australia), Pty. Ltd., Bain Capital Credit, Ltd., Bain Capital Investments (Europe) Limited, Bain Capital Investments (Ireland) Limited, Bain Capital Credit CLO Advisors, LP, Bain Capital Credit U.S. CLO Manager, LLC, Bain Capital Credit U.S. CLO Manager II, LP, Bain Capital Credit (Asia) Limited, Bain Capital (Singapore) PTE. LTD, Bain Capital Private Equity Japan LLC, BCPC Advi ...

Company Overview & Strategy - Neuronetics and Greenbrook have combined to leverage scale and treat more mental health patients, having treated 213,500 unique patients and administered 7,620,000 treatments[13] - The company is focused on driving accelerated growth, realizing cost reductions, and transforming its financial profile to deliver mid-teens revenue growth and near-term profitability[21] - A key strategy involves expanding the Better Me Provider (BMP) network, with over 375 BMP clinics in 49 states[17], and increasing patient flow through referral networks and optimized digital marketing[70] Financial Performance & Guidance - Full year 2024 consolidated adjusted net pro forma revenue was $129.4 million[13, 79] - Q1 2025 revenue reached $32.0 million, an 84% increase compared to Q1 2024 on a reported basis and a 7% increase on an adjusted pro forma basis[88, 95] - The company anticipates revenue between $149 million and $155 million for FY 2025, representing a 15% to 19% pro forma year-over-year growth[83] - The company expects to achieve cash flow positive status beginning in Q3 2025[83] Cost Synergies - The company has identified $22.6 million in annualized expected cost savings through various initiatives, including NNI RIF/Spend Reductions ($16.2 million), Greenbrook Clinics savings ($5.1 million), and Additional Reductions ($1.3 million)[77] Clinical & Market Position - NeuroStar is the first FDA-cleared TMS treatment for adolescent depression and is positioned as a first-line treatment[44] - Real-world clinical results show 83% improvement in depression symptoms and 62% symptom relief (remission) for patients with MDD[39] - Practices attending NeuroStar University (NSU) have started 40% more patients than non-attendees since Q3 2022[55], and performed 30% more treatment sessions in Q1 2025[60]

Q1 2025 EARNINGS PRESENTATION MAY 6, 2025 SAFE HARBOR STATEMENT This presentation contains, and the conference call will contain, forward-looking statements under the Private Securities Litigation Reform Act safe harbor provisions. These statements, which include our expectations for spending in our industry and guidance for future financial performance, are based on management's current expectations and should be viewed with caution. They are subject to various risks and uncertainties that could cause actu ...

MAY 2025 FORWARD LOOKING STATEMENTS AND MARKET DATA Madison Square Garden Entertainment Corp. (the "Company" or "MSG Entertainment") has filed with the Securities and Exchange Commission an Annual Report on Form 10-K for the year ended June 30, 2024 (the "Annual Report") and Quarterly Reports on Form 10-Q for the quarters ended September 30, 2024, December 31, 2024 and March 31, 2025 (the "Quarterly Reports"). The Annual Report and the Quarterly Reports contain extensive disclosure about the Company and its ...

Q1 2025 Earnings Call Heron Therapeutics May 6, 2025 Forward-looking Statements and Non-GAAP Disclosures This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date hereof and are subject to certain risks and uncertainties that could cause actual results to differ materially. Examples of forward-looking statements include, ...

Q1 2025 EARNINGS May 6, 2025 Forward-Looking Statements This presentation contains a number of forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include predictions of future results or activities and may contain the words "expect," "believe," "will," "can," "anticipate," "estimate," "project," "should," "would," or words or phrases of similar meaning. You are cautioned not to rely on these forward- ...

Financial Performance - Revenue decreased by 10% year-over-year, with Q1 2025 revenue at $2278 million compared to $2520 million in Q1 2024[3, 4] - GAAP gross margin increased by 70 basis points year-over-year to 394% in Q1 2025[3, 21] - GAAP operating income significantly decreased by 91% year-over-year, from $191 million in Q1 2024 to $18 million in Q1 2025[4] - Net income decreased by 84% year-over-year, from $241 million in Q1 2024 to $38 million in Q1 2025[4] - Earnings per diluted share (EPS) decreased by 83% year-over-year, from $052 in Q1 2024 to $009 in Q1 2025[3, 4] - Adjusted EBITDA decreased by 19% year-over-year, from $403 million in Q1 2024 to $327 million in Q1 2025[3, 4, 24] - Adjusted EPS decreased by 38% year-over-year, from $050 in Q1 2024 to $031 in Q1 2025[3, 4, 26] Revenue and Market Trends - Emerging growth products accounted for 51% of total revenue[3] - Sales declined year-over-year in North America due to lower revenue in cutting and welding applications[10] - European sales declined primarily due to lower demand in cutting and welding applications and exit from Russia[10] Financial Guidance - The company expects Q2 2025 revenue to be between $210 million and $240 million[15]

Financial Performance - Q1 2025 - Total net revenue for Q1 2025 was $777882 thousand, a decrease compared to $856645 thousand in Q1 2024[6] - Net loss attributable to AdaptHealth Corp was $(7207) thousand in Q1 2025, compared to a net income of $50262 thousand in Q1 2024[6] - Adjusted EBITDA for Q1 2025 was $127938 thousand, with an Adjusted EBITDA Margin of 164%, compared to $158485 thousand and 200% respectively in Q1 2024[6] - Non-Acquired Net Revenue Growth was (21)% in Q1 2025[13] Revenue by Segment - Q1 2025 - Net sales revenue totaled $495522 thousand, representing 637% of total net revenue[11] - Net revenue from fixed monthly equipment reimbursements was $249535 thousand, accounting for 321% of total net revenue[11] - Net revenue from capitated revenue arrangements reached $32825 thousand, which is 42% of total net revenue[12] Debt and Share Information - Q1 2025 - Total long-term debt amounted to $2017434 thousand, with net debt at $1963784 thousand[22] - The Consolidated Total Leverage Ratio was 298[22] - The number of common shares outstanding as of March 31, 2025, was 134941 thousand[23]

L.B. Foster Company Earnings Presentation Nasdaq - FSTR May 6, 2025 Safe Harbor Disclaimer Safe Harbor Statement This presentation may contain "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements provide management's current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or cur ...

Financial Performance - Boise Cascade's Q1 2025 sales were $1.5 billion, a decrease of 7% compared to Q1 2024[4] - Net income for Q1 2025 was $40.3 million, or $1.06 per share, significantly lower than the $104.1 million, or $2.61 per share, in Q1 2024[4] - Adjusted EBITDA decreased by 46%, from $168.5 million in 1Q 2024 to $91.6 million in 1Q 2025[6] Segment Performance - Building Materials Distribution (BMD) sales were $1.4071 billion in 1Q 2025, down from $1.505 billion in 1Q 2024[6] - Wood Products sales were $415.8 million in 1Q 2025, down from $468.9 million in 1Q 2024[6] - BMD segment EBITDA was $62.8 million in 1Q25, compared to $83.6 million in 1Q24[28] - Wood Products segment EBITDA was $40.2 million in 1Q25, compared to $95.6 million in 1Q24[28] Capital Allocation - Capital expenditures totaled $53 million in 1Q 2025, with $31 million allocated to Wood Products and $22 million to BMD[23] - Share repurchases amounted to $54 million in 1Q 2025, with a total of $71 million repurchased year-to-date through April[23] - $10 million in dividends were paid in 1Q 2025[23] Outlook - The company anticipates that most housing starts forecasts ranging between flat to mid-single digit year-over-year declines[24]